TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07071090: An Open-Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Sponsor: Heronova Pharmaceuticals · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 32 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,764,608

Rescue Site Savings

+$1,822,128

Unlock Full NCT07071090 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07071090 Rescue Dossier →